A detailed history of Abbot Financial Management, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Abbot Financial Management, Inc. holds 9,441 shares of BMY stock, worth $554,941. This represents 0.25% of its overall portfolio holdings.

Number of Shares
9,441
Previous 9,541 1.05%
Holding current value
$554,941
Previous $396,000 23.23%
% of portfolio
0.25%
Previous 0.22%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$39.66 - $51.75 $3,965 - $5,175
-100 Reduced 1.05%
9,441 $488,000
Q2 2024

Aug 09, 2024

SELL
$40.25 - $52.99 $4,387 - $5,775
-109 Reduced 1.13%
9,541 $396,000
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $103,876 - $117,776
2,165 Added 28.92%
9,650 $523,000
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $16,968 - $20,247
350 Added 4.91%
7,485 $384,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $105,649 - $118,132
1,825 Added 34.37%
7,135 $414,000
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $66,895 - $74,277
1,050 Added 24.65%
5,310 $339,000
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $29,104 - $34,463
425 Added 11.08%
4,260 $306,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $19 - $11,526
150 Added 4.07%
3,835 $273,000
Q4 2021

Feb 15, 2022

SELL
$53.63 - $62.52 $160,890 - $187,560
-3,000 Reduced 44.88%
3,685 $230,000
Q3 2021

Nov 04, 2021

BUY
$59.17 - $69.31 $50,294 - $58,913
850 Added 14.57%
6,685 $396,000
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $148,584 - $161,808
2,400 Added 69.87%
5,835 $390,000
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $203,832 - $229,251
3,435 New
3,435 $217,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Abbot Financial Management, Inc. Portfolio

Follow Abbot Financial Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abbot Financial Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Abbot Financial Management, Inc. with notifications on news.